Insider filing · SGHT

Staffan Encrantz bought $291K of Sight Sciences (SGHT)

Executed Jun 5 2025, disclosed Jun 6 2025, 1 day later.

Over the 21 trading sessions from the disclosed entry session (Jun 6 2025), the stock returned -16.4% (delay-adjusted); from the execution session (Jun 5 2025), -18.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

SE Staffan Encrantz Director profile →

Staffan Encrantz (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Sight Sciences, Inc. (SGHT). Across 1 priced purchase filing, the average 21-session return was -20.6% from execution and -25.6% from disclosure (delay-adjusted; derived). The largest single filing was $116K of SGHT (13,958 sh × $8.31, as filed), executed Dec 16 2025.

SGHT Sight Sciences, Inc. SGHT · Healthcare · 14 filings in 24 months ticker →

Healthcare · Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical te…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→